NaiVec Participates in Europe's Largest Implant Expo... "Negotiating Volume Expansion"

Naibec announced on the 25th that it will participate in ‘EAO BERLIN 2023,’ Europe’s largest implant exhibition. At this exhibition, Naibec will hold a corporate forum to share clinical outcomes of its core implant bone regeneration materials. It also plans to participate in the exhibition to expand its global network and negotiate increased supply volumes with key customers.

At the corporate forum held on the first day of the exhibition, Naibec will introduce the outstanding clinical results of its core products such as ‘OCS-B,’ ‘OCS-B Collagen,’ and ‘Regenomer.’ These products are already successfully undergoing ‘Post-Market Clinical Follow-up (PMCF)’ in Europe. The clinical outcomes of ‘OCS-B Collagen,’ currently being conducted at Frankfurt University Hospital and Seoul National University Dental Hospital, have also been confirmed to be excellent.

During the exhibition, Naibec plans to open a corporate booth to expand the global sales network for its key bone regeneration material products. It will focus on discussions regarding increasing supply volumes in the global market, including Europe, with major partners such as ‘Straumann’ and ‘Nobel Biocare.’

EAO is the European Association for Osseointegration, held from the 28th to the 30th in Berlin, Germany, and is the largest global event related to the dental implant industry. Implant companies and dental specialists from around the world also attend in large numbers. EAO hosts various seminars including the exhibition, ▲corporate-hosted forums ▲invited lectures by world-renowned speakers and research presentations ▲latest industry trends.

A Naibec representative said, “We expect our flagship products to attract global market attention through the corporate forum, leading to the largest number of order consultations ever.” He added, “We will conduct in-depth discussions on sales expansion, including next year’s sales plans, based on the transition to European MDR certification with our major clients.”

He continued, “Having participated in EAO for 11 years, we confirmed that our status in the global market has significantly risen as a major company hosting a forum.” He emphasized, “We will do our best to prepare so that this EAO exhibition becomes an opportunity to greatly expand overseas market sales.”

Naibec also plans to actively promote ‘Pepticol EasyGraft,’ a next-generation tissue regeneration biomaterial preparing for domestic clinical entry, at this EAO. Pepticol EasyGraft was submitted for clinical trial application to the Korean Ministry of Food and Drug Safety in May and is currently under review.

Pepticol EasyGraft is a bio-material that integrates high-purity collagen functional active substances. By applying dual-functional peptides, it has excellent effects in suppressing periodontitis and promoting bone regeneration, making it applicable not only in dentistry but also in orthopedics, surgery, dermatology, and various other fields.

This content was produced with the assistance of AI translation services.